DGAP-News: Eckert & Ziegler: Significant improvement in cost items in the first half year


 
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarterly / Interim Statement/Forecast Eckert & Ziegler: Significant improvement in cost items in the first half year 02.08.2016 / 07:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, 2 August 2016. In the first half of the year, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist for isotope-based applications in medicine, science and industry headquartered in Berlin, posted a EUR 1.1 million rise in sales to EUR 70.1 million compared to the same period in the prior year (+ 2 %). Currency effects and acquisitions were irrelevant, the nominal growth was largely based on organic growth. The sharpest rise in sales of EUR 2.1 million, or 12 %, to EUR 19.4 million was posted by the Radiopharma segment. While sales of equipment and cyclotron products remained more or less unchanged year on year, sales of pharmaceutical radioisotopes posted double-digit growth. The Isotope Products segment saw sales rise by EUR 1.4 million, or 4 %, to EUR 40.2 million, while, as expected, sales in the Radiation Therapy segment shrank by EUR 2.7 million, or 18 %, to EUR 12.0 million following the prior year's disposal of two divisions. Group earnings per share fell by EUR 0.53, or 37 %, year on year to EUR 0.89. This corresponds more or less exactly to the expected value, which provides for earnings of EUR 1.80 per share for the full year. If the earnings for the first half of the year are only calculated on the basis of the continuing operations and eliminating the losses for 2016 that arose from the winding-down of a Californian subsidiary, earnings per share amounted to EUR 0.98, that is to say EUR 0.10 more. The scheduled decline in profits was due to the EUR 5.9 million drop in extraordinary income which stood at a record figure of EUR 9.2 million in the prior year as a result of, among other things, the sale of an investment (OctreoPharm Sciences). This was compounded in 2015 by a EUR 1.2 million rise in the financial result - mainly as a result of exchange rate gains. If extraordinary income and the financial result are excluded for both halves of the year, there has been a significant improvement in the results of operations. While sales remained more or less unchanged, the Group's gross margin rose by EUR 1.3 million and administrative and selling expenses fell by EUR 2.2 million. The disposals of loss-bringer operations and the closure of unprofitable subsidiaries enabled the Group to reduce its cost base by EUR 3.5 million, or 5 % of sales, within a period of twelve months. Compared to 2015, more or less constant sales of EUR 140 million are expected for 2016. Profit is likely to decline to around EUR 1.80 per share due to the absence of positive one-off effects. The complete quarterly financial statements can be viewed under: http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/ englisch/euz216e.pdf About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 700 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com --------------------------------------------------------------------------- 02.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 487719 02.08.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 37,220 Halten 788,02
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
23,26 26,33 0,89 40,95
KBV KCV KUV EV/EBITDA
3,56 16,63 3,20 12,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 0,05 0,13 28.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2024 09.08.2024 14.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-10,57% 0,20% -9,88% -26,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ